The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel therapies and the identification of new genetic markers. The current most effective therapies for CLL include venetoclax, obinutuzumab and BTK inhibitors, whilst ongoing clinical trials are investigating the use of BTK inhibitors in combination with BCL-2 inhibitors. Furthermore, novel genomic markers are increasingly being used to guide treatment decisions, as well as for prediction and prognostication purposes, and research into the optimal sequencing of targeted therapies is also showing promise in improving outcomes for patients who develop resistance to BCL-2 and BTK inhibitors.
In this podcast, Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy, Barbara Eichhorst, MD, of University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, of Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Adrian Wiestner, MD, PhD, of the National Institutes of Health, Bethesda, MD, and Richard Rosenquist, MD, of the Karolinska Institute, Stockholm, Sweden, share some of the latest updates in CLL treatment, as presented at the 19th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting in 2021.
Texas MPN Workshop 2021: updates on interferons for MPNs
EHA 2021: real-world data on myeloma, lymphoma and CLL
Novel BTK inhibitors for NHL
Latest updates on T-cell therapies for non-Hodgkin lymphoma
Novel CD20/CD3 bispecific antibodies in NHL
Latest updates on CAR-T therapy for lymphoma
EHA & ICML 2021: updates in Hodgkin lymphoma
Latest transplant updates from EHA 2021
Key updates on CAR-T therapy for multiple myeloma
The Lymphoma Sessions: highlights from EHA and ICML 2021
The CLL Sessions: highlights from EHA and ICML 2021
EHA 2021: updates on treatment for MDS
iwNHL 2021: immunotherapy and the microenvironment
The Myeloma Sessions: highlights from EHA and ASCO 2021
EHA 2021: key trial updates in myelofibrosis
The MPN Sessions: highlights from EHA and ASCO 2021
The MDS Sessions: highlights from ASCO/EHA 2021
EHA 2021: fixed-duration therapies and sequencing in CLL
The AML Sessions: highlights from ASCO/EHA 2021
EHA 2021: key trial updates in myeloma
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive